Michael Iglesia

Oct 30, 2024 | nature.com | Reyka G. Jayasinghe |Michael Iglesia |John Herndon |Austin N. Southard-Smith |Jacqueline L. Mudd |Alla Karpova | +16 more

AbstractTo study the spatial interactions among cancer and non-cancer cells1, we here examined a cohort of 131 tumour sections from 78 cases across 6 cancer types by Visium spatial transcriptomics (ST). This was combined with 48 matched single-nucleus RNA sequencing samples and 22 matched co-detection by indexing (CODEX) samples. To describe tumour structures and habitats, we defined ‘tumour microregions’ as spatially distinct cancer cell clusters separated by stromal components.

Jun 3, 2024 | onclive.com | Michael Iglesia

CommentaryVideoJune 3, 2024Author(s):Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making. Michael Iglesia, MD, PhD, instructor, John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, discusses the potential role of disease etiology in frontline hepatocellular carcinoma (HCC) treatment decision-making.

May 14, 2024 | onclive.com | Michael Iglesia

May 14, 2024Michael Iglesia, MD, PhD, discusses uncertainties surrounding the selection of second-line treatment approaches in hepatocellular carcinoma. Michael Iglesia, MD, PhD, instructor, John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, discusses unmet needs and uncertainties surrounding second-line therapy considerations in hepatocellular carcinoma (HCC).

May 3, 2024 | onclive.com | Michael Iglesia

Michael Iglesia, MD, PhD, instructor, John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, discusses key efficacy and safety data from the phase 3 COSMIC-312 trial (NCT03755791) of first-line cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) in hepatocellular carcinoma (HCC).

Nov 1, 2023 | nature.com | Alla Karpova |Yize Li |Austin N. Southard-Smith |Michael Iglesia |Reyka G. Jayasinghe |Matthew Wyczalkowski | +17 more

AbstractChromatin accessibility is essential in regulating gene expression and cellular identity, and alterations in accessibility have been implicated in driving cancer initiation, progression and metastasis1,2,3,4. Although the genetic contributions to oncogenic transitions have been investigated, epigenetic drivers remain less understood.